Powering EV research to realize earlier disease detection.
We're speeding up the fight against cancer and other diseases by putting our breakthrough technology in the hands of leading researchers.
Today’s diagnostic methods are not good enough. They catch cancer and other diseases too late.
Research has begun a focus on Extracellular Vesicles (EVs) for answers to earlier disease detection, diagnosis, and therapies. EVs drive inter-cellular communication within our bodies and hold a key to earlier disease detection. Researchers need advanced technologies to simplify and reproducibly accelerate the exploitation of EVs for discovery of highly sensitive techniques for disease detection and diagnosis.
EXOKĒRYX is leveraging semiconductor technology to power best-in-class tools for isolation, characterization, and analysis of extracellular vesicles. Our product roadmap includes automated chip-based technology that leverages dielectorphoresis to isolate EVs with higher recovery and purity. Decoding Extracellular Vesicle biomarkers will allow researchers to define unique fingerprints for earlier disease and cancer detection.
Ultimately, powered by our chip-based sensor, we will deliver solutions with the sensitivity and affordability necessary to make it possible for everyone to be tested yearly for cancer and other diseases.
Together with researchers, we can drive discovery, detect cancer earlier, and save lives.
-
Industry
-
Biotechnology Research
-
Company size
-
2-10 employees
-
Headquarters
-
San Diego, California
-
Type
-
Privately Held
-
Founded
-
2021